Usefulness of weightlifting training in improving strength and maximal power output in coronary artery disease.

The effects of 10 weeks (20 sessions) of combined weightlifting and aerobic training (n = 10) were compared with the effects of aerobic training alone (n = 8) on indexes of strength and aerobic exercise capacity in 18 men with coronary artery disease (CAD). Initial test performance was similar between groups. After aerobic training, the maximal load that could be lifted once only (1-repetition maximum) in single-arm curl, single-leg press and single-knee extension exercises increased by 13% (11.8 to 13.3 kg; p less than 0.01), 4% (97.0 to 101.0 kg; difference not significant) and 5% (28.2 to 29.7 kg; difference not significant), respectively; corresponding gains with combined weightlifting and aerobic training were 43% (12.2 to 17.4 kg; p less than 0.01), 21% (99.0 to 120.0 kg; p less than 0.01) and 24% (29.0 to 36.0 kg; p less than 0.01). After aerobic training, the initial 1-repetition maximum could be lifted an average of 4 times, compared with 14 times after combined training. Maximal progressive incremental cycle ergometer power output increased by 2% in the aerobic control group (1,088 to 1,113 kpm/min; difference not significant) and by 15% (1,030 to 1,180 kpm/min; p less than 0.05) in the experimental group. Cycling time at 80% of initial maximal power before attaining a Borg (0 to 10) rating of perceived exertion of 7 (very severe) increased by 11% (604 to 672 seconds; difference not significant) and by 109% (541 to 1,128 seconds; p less than 0.05) in the control and weight-trained patients, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

The incentive effect and sleep deprivation.

In order to examine the effect of a small amount of sleep following 3 3/4 days (90 h) of wakefulness, 10 infantry soldiers took part in a laboratory-based experiment. At the end of the vigil, a 2-h sleep was preceded and followed by a cognitive test session consisting of encoding and decoding. In order to simulate a realistic situation, subjects were not told the scheduled length of their vigil until a few hours before their 2-h sleep. Following the test-sleep-test period, 27 h were allowed for sleep and rest. Results indicated that after 3 nights without sleep, performance was, on the average, 55% of the control values. During the test session before the 2-h sleep, performance improved by 30%, to 85% of control values, indicating the considerable effect that incentive can have on even severely sleep-deprived subjects. The reserve mental capacity demonstrable during sleep deprivation indicates the caution that is needed if the effects of "undiluted" sleep loss are sought; it also emphasises once again the lack of knowledge concerning the function of sleep.

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

BACKGROUND: Although lithium has been the most commonly used maintenance treatment in bipolar disorder for several decades, valproate is being used increasingly - especially in the United States of America. There is a need to clarify whether the increasingly prominent prophylactic role of valproate in bipolar disorder is justified. OBJECTIVES: To review the effectiveness of valproate, relative to placebo, other mood stabilisers and antipsychotics, in the prevention and/or attenuation of acute episodes of bipolar disorder. The effectiveness of valproate was considered in terms of mood symptoms, mortality, general health, social functioning, adverse effects and overall acceptability to patients. SEARCH STRATEGY: The CCDAN group search strategy was used. The following databases were searched: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR), The Cochrane Controlled Clinical Trials Register (CCCTR), EMBASE, MEDLINE, LILACS, PsycLIT and Psyndex. Reference lists of relevant papers and major textbooks of mood disorder were examined. Authors, other experts in the field and pharmaceutical companies were contacted for knowledge of suitable published or unpublished trials. SELECTION CRITERIA: Randomised controlled trials which compared valproate with placebo, alternative mood stabilisers (including lithium and carbamazepine) or neuroleptics, where the stated intent of intervention was the maintenance treatment of bipolar disorder. Participants were males and females of all ages with a diagnosis of bipolar disorder however diagnosed, approximating to ICD 10 Code F31 and DSM IV 296, but including patients diagnosed as ICD-9 manic depressive psychosis and DSM-III and DSM-IIIR bipolar disorder. DATA COLLECTION AND ANALYSIS: Data were extracted from the original reports individually by two reviewers. The main outcomes to be assessed were: 1. The effectiveness of valproate treatment in preventing or attenuating further episodes of bipolar disorder, including its effectiveness in rapid cycling disorder. 2. The acceptability of valproate treatment to patients. 3. The prevalence of side-effects. 4. Mortality on valproate treatment. Outcomes concerning relapse/recurrence were analysed excluding data from discontinuation studies, which were to be analysed separately. Sub-group analyses were to be performed to examine the effects of valproate treatment in rapid cycling bipolar disorder and previous mood stabiliser non-responders. Data were analysed using Review Manager version 4.1. MAIN RESULTS: One trial of 12 months duration with 372 participants was identified comparing lithium, divalproex and placebo. It had several methodological limitations. The primary analysis of time to occurrence of mood episode described in the main trial report found no reliable difference between the treatments, although there was a trend for divalproex to be more effective than lithium. In the analysis in this review, patients taking divalproex who left the study because of the occurrence of an mood episode were significantly less in number than those on placebo (RRR 37%; RR 0.63; 95% CI 0.44 to 0.90). There was no significant difference in the numbers of patients in receipt of divalproex compared with those in receipt of lithium who left the study because they suffered any mood episode. (RRR 22%; RR 0.78; 95% C.I. 0.52 to 1.17). There was insufficient information to allow sub-group analyses of rapid-cycling disorder. The divalproex group had significantly more patients suffering tremor (RRI 223%; RR 3.23; 95% C.I. 1.85 to 5.62), weight gain (RRI 187%; RR 2.87; 95% C.I. 1.34 to 6.17) and alopecia (RRI 143%; RR 2.43; 95% C.I. 1.05 to 5.65) than the placebo group. In comparison with the lithium, divalproex was associated with more frequent sedation (RRI 58%; RR 1.58; 95% C.I. 1.08 to 2.32) and infection (RRI 107%; RR 2.07; 95% C.I. 1.16 to 3.68), but less suffered thirst (RRR 62%; RR 0.38; 95% C.I. 0.18 to 0.81) and polyuria (RRR 57%; RR 0.43; 95% C.I. 0.22 to 0.82). REVIEWER'S CONCLUSIONS: In view of the equivocal findings of this review, conclusions about the efficacy and acceptability of valproate compared to placebo and lithium cannot be made with any degree of confidence. With current evidence, patients and clinicians would probably wish to use lithium before valproate for maintenance treatment. At present, the observed shift of prescribing practice to valproate is not based on reliable evidence of efficacy

The military performance of soldiers in sustained operations.

Two 9-d tactical defensive exercises were carried out. The first assessed and compared the performance of three platoons of infantry scheduled for either 0, 1.5, or 3 h of sleep in every 24 h, and the second determined whether soldiers are likely to remain militarily effective during a period of partial sleep loss following a period with no scheduled sleep at all. To this end, 10 infantry soldiers were scheduled for 4 h of sleep in every 24 for a 6-d period following a 3.75-d period without any scheduled sleep. Performance, physical fitness, and mood were assessed throughout both exercises. Results indicated that the effects of sleep loss are psychological rather than physiological; soldiers are likely to be militarily ineffective after 48-72 h without sleep; and a small amount of recovery sleep relative to the amount lost has very beneficial effects.

Sustained performance and some effects on the design and operation of complex systems.

Man, increasingly the limiting element in the military man-machine system, must often operate for several days in a high-risk environment with little or no sleep. It is necessary, therefore, to have some knowledge of the likely effects of sleep deprivation to predict his behaviour and minimize the adverse effects of sleep loss. The early work of the Army Personnel Research Establishment (APRE) concentrated on studying the infantryman in field trials, characterized by more realism and of greater length than previously attempted. Although measures of cognitive functioning were included in these trials, continuous cognitive performance was not assessed, nor was performance on complex tasks. An opportunity to remedy this situation arose because of a newer study concerned with controlling a removely-piloted air vehicle from a ground control station (GCS). A 65-hour experiment was designed during which subjects performed continuously either on the GCS simulator or on a battery of cognitive tests, mood scales, and physiological assessments. Results showed that whereas performance showed the usual deterioration in the test battery, it held up remarkably well on the simulator. Several reasons for this difference are suggested.

Psychosocial interventions as an adjunct to pharmacotherapy in bipolar disorder.

OBJECTIVE: To summarize the evidence and make treatment recommendations regarding the use of psychosocial interventions as an adjunct to pharmacotherapy for bipolar disorder. METHODS: We reviewed published outcome studies since 1975 identified in MEDLINE and PsychLIT searches. RESULTS: Available studies are initial and of highly variable methodological rigour. Evidence is most robust for the efficacy of psychoeducation and family therapy, and these received the highest level of recommendation as interventions. Group therapy, cognitive-behavioural therapy, and behavioural family management therapy are supported by weaker evidence and received a lower-level treatment recommendation. Availability of only a single interpersonal and social rhythms therapy trial limited the confidence of the recommendation for this intervention. CONCLUSIONS: Controlled trials are needed to replicate early outcome studies and guide treatment recommendations. Accumulated evidence of favourable psychosocial intervention outcomes supports, with variable confidence, their use as adjuncts to pharmacotherapy in the treatment of bipolar disorder.

Treatment of mania, mixed state, and rapid cycling.

OBJECTIVES: To summarize the quality of evidence for the efficacy of different biological treatments in mania, mixed state, and rapid cycling and to propose guidelines for treatment of these conditions. METHOD: Articles published on treatment of acute mania, mixed states, and rapid cycling were reviewed and rated for quality of evidence using Periodic Health Examination guidelines. RESULTS: Lithium and divalproex sodium are effective in classical pure mania, whereas divalproex sodium and carbamazepine are likely more effective in mixed states. Divalproex sodium is likely more efficacious than carbamazepine and lithium when the mania is part of a rapid-cycling course. Typical neuroleptics are efficacious in acute mania, particularly in the presence of marked psychotic symptoms. Atypical neuroleptics can be useful in refractory mania. Some benzodiazepines do have antimanic effects, but they are increasingly being shown to have usefulness as adjuncts to mood stabilizers or neuroleptics rather than as primary antimanic agents. Electroconvulsive therapy (ECT) is an efficacious and broad-spectrum treatment. CONCLUSIONS: Mania can present with or without mood-congruent or mood-incongruent psychotic features and as part of a rapid-cycling or nonrapid-cycling course. Mixed state is a common presentation in an acutely manic patient. The accurate assessment of these issues can serve as a guide in determining treatment options and choices.

Bipolar depression: treatment options.

OBJECTIVE: To review studies on treatments for bipolar depression and make recommendations for practising clinicians treating patients with bipolar depression. METHOD: Studies that examined various treatments for bipolar depression were evaluated and rated for evidence of efficacy using Periodic Health Examination criteria. The rating for classification of recommendation for an intervention was made taking both the efficacy and the side effects into consideration. RESULTS: Mood stabilizers, cyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and electroconvulsive therapy (ECT) are all effective in treating bipolar depression. Almost all antidepressant treatments with the exception of mood stabilizers have been reported to induce a manic-hypomanic switch and rapid cycling. CONCLUSIONS: Mood stabilizers, lithium in particular, are recommended as the first-line treatment. Addition of a second mood stabilizer or a cyclic antidepressant would be an appropriate next step. Newer agents such as lamotrigine offer considerable promise in treating bipolar depressed patients.

The foundations of effective management of bipolar disorder.

OBJECTIVES: To understand the epidemiology and course of bipolar disorder; to outline the importance of accurate and reliable diagnosis of bipolar disorder both on a cross-sectional and longitudinal basis; and to emphasize the value of a collaborative therapeutic relationship, psychoeducation, and psychotherapy. METHODS: A brief review of relevant literature to deal with the issues of diagnosis and laying the foundations for effective treatment. RESULTS: Bipolar disorder may well be a heterogeneous group of conditions with varying forms of biphasic mood dysregulation and a changing course across a lifetime. A collaborative therapeutic relationship, psychoeducation, and psychotherapy can be the basis for effective management. CONCLUSIONS: As the concept of bipolar disorder has broadened, the condition is being identified with increasing frequency in many clinical settings. It is a relapsing and recurring condition. It is now recognized that in addition to rational pharmacotherapy, there is a need to encourage a high level of treatment adherence while providing a holistic package of interventions.

Continuation and prophylactic treatment of bipolar disorder.

OBJECTIVES: To summarize the evidence for efficacy from published literature of biological treatments in the continuation and maintenance phases of bipolar disorder, as well as the recommendations about different treatment options made by the working group within the Bipolar Sub-Committee of the Canadian Network for Mood and Anxiety Treatments (CANMAT). METHODS: A review of relevant published literature and proceedings of international conferences was conducted. The quality of evidence was assessed and classified according to the Periodic Health Examination criteria. Treatment recommendations of the working group were based on quality of evidence, a consensus of expert views, and the opinions of psychiatrists and family physicians from across Canada. RESULTS: There is overwhelming evidence for the efficacy of lithium in the prophylaxis of bipolar disorder. The evidence for carbamazepine is less robust. There are no published double-blind studies with adequate numbers of subjects treated with divalproex sodium. CONCLUSIONS: During and at the end of the continuation phase it is recommended that mood stabilizers should remain the mainstay of therapy and that other treatments should be gradually discontinued or maintained only if there is valid reason to do so. Efficacious maintenance treatment can reduce morbidity and mortality significantly and improve patients' quality of life.